Dose optimization in drug development: Role of phase IV trials

International Congress Series

Volumn 1220, Issue C, 2001, Pages 51-65

  Joubert, Pieter H ^a  

^a Novartis Pharma   (Switzerland)

Author keywords

Formulation; Life cycle management; Phase IV; Post marketing; Risk benefit

Indexed keywords

EID: 56749125725     PISSN: 05315131     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0531-5131(01)00286-2     Document Type: Article

References (12)

1. Collier, A.C., Coombs, R.W., Schoenfeld, D.A., et al. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. N. Engl. J. Med. 334 (1996), 1011–1017.
2. Gieschke, R., Fotteler, B., Buss, N., Steimer, J.-L., Relationship between exposure to saquinavir monotherapy and antiviral response in HIV-positive patients. Clin. Pharmacokinet. 37 (1999), 75–86.
3. Jorga, K., Buss, N., Pharmacokinetic drug interaction with saquinavir soft gelatin capsule., 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, 26–29 September, 1999, American Society for Microbiology Abstract 0339.
4. Kilby, J.M., Sfakianos, G., Gizzi, N., et al. Safety and pharmacokinetics of once-daily regimens of soft-gel capsule saquinavir plus minidose ritonavir in human immunodeficiency virus-negative adults. Antimicrob. Agents Chemother. 44 (2000), 2672–2678.
5. Paredes, R., Puig, T., Arno, A., High dose saquinavir plus ritonavir: long term efficacy in HIV-positive protease inhibitor-experienced patients and predictors of virologic response. J. Acquired Immune Defic. Syndr. 22 (1999), 132–138.
6. Parish, R.C., Miller, R.J., Adverse events of angiotensin converting enzyme (ACE) inhibitors. Drug Saf. 7 (1992), 14–31.
7. Kleinbloesem, C.H., Van Brummelen, P., Danhof, M., et al. Rate of increase in the plasma concentration of nifedipine as a major determinant of its haemodynamic effects in humans. Clin. Pharmacol. Ther. 41 (1987), 26–30.
8. Lewis, E.J., Hunsicker, L.G., Bain, R.P., Rohde, R.D., The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N. Engl. J. Med. 329 (1993), 1456–1462.
9. Bristow, M.R., Pathophysiologic and pharmacologic rationales for clinical management of chronic heart failure with beta-blockers. Am. J. Cardiol. 71 (1993), 12C–22C.
10. Bristow, M.R., Gilbert, E.M., Abraham, W.T., et al. Congestive cardiac failure/myocardial disease: carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation 94 (1996), 2807–2816.
11. Pullar, T., Birtwell, A.J., Wiles, P.G., et al. Use of a pharmacologic indicator to compare compliance with tablets prescribed to be taken once, twice or three times daily. Clin. Pharmacol. Ther. 5 (1988), 540–545.
12. Gibaldi, M., Failure to comply: a therapeutic dilemma and the balance of clinical trials. J. Clin. Pharmacol. 36 (1996), 674–682.